FDA Accepts Arcutis sNDA for ZORYVE (roflumilast) Cream 0.05% in Infants Down to 3 Months With Atopic Dermatitis
Key Dates
What Happened
On July 8, 2026, Arcutis announced the FDA accepted its supplemental NDA to expand ZORYVE cream 0.05% for mild to moderate atopic dermatitis to infants aged 3 to 24 months. The FDA set a PDUFA target action date of February 23, 2027. The application is backed by Arcutis' INTEGUMENT-INFANT Phase 2 study and a Phase 1 pharmacokinetic study in infants.
Who It Affects
This is most relevant to pediatric dermatologists, general pediatricians who manage early eczema, children's hospitals, and caregiver-facing support programs for infants with chronic skin disease. It also matters to companies and investors watching how far branded dermatology therapies can push into younger pediatric populations through formal FDA pathways rather than off-label use.
Business Implications
This is a watch item, not a market change yet — nothing changes operationally until the FDA acts. But the acceptance matters because it extends the same pediatric-label-wave logic deeper into infancy, where treatment options are thinner and caregiver concern about steroid exposure is higher. If approved, the result would be another example of incumbents using pediatric trials to open a younger specialty market, creating downstream demand for prescribing support, access navigation, and longitudinal adherence infrastructure.